- Home
- AUTL vs GBAB Comparison
AUTL vs GBAB Comparison
Compare AUTL & GBAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | AUTL | GBAB |
|---|---|---|
| Founded | 2014 | N/A |
| Country | United Kingdom | United States |
| Employees | 752 | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 385.9M | 396.7M |
| IPO Year | 2025 | 2010 |
Fundamental Metrics
Financial Performance| Metric | AUTL | GBAB |
|---|---|---|
| Price | $1.46 | $13.78 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $8.50 | N/A |
| AVG Volume (30 Days) | ★ 1.1M | 89.3K |
| Earning Date | 05-14-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $10,120,000.00 | N/A |
| Revenue This Year | $80.32 | N/A |
| Revenue Next Year | $53.96 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 496.00 | N/A |
| 52 Week Low | $1.18 | $13.51 |
| 52 Week High | $2.60 | $15.94 |
Technical Indicators
Market Signals| Indicator | AUTL | GBAB |
|---|---|---|
| Relative Strength Index (RSI) | 45.27 | 29.72 |
| Support Level | $1.37 | $13.51 |
| Resistance Level | $1.52 | $15.47 |
| Average True Range (ATR) | 0.10 | 0.16 |
| MACD | -0.01 | -0.05 |
| Stochastic Oscillator | 24.66 | 10.61 |
Price Performance
Historical ComparisonAbout AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8. Company's T cell programming technologies tailors therapies to address the specific disease targeting and introduce new programming modules into a patient's T cells to give those T cells improved properties to recognize target cells and overcome fundamental disease defense mechanisms.
About GBAB Guggenheim Taxable Municipal Bond & Investment Grade Debt Trust of Beneficial Interest
Guggenheim Taxable Municipal Bond & Investment Grade Debt Trust is a diversified closed-end management investment company. Its investment objective is to provide current income with a secondary objective of long-term capital appreciation. Its products include Mutual funds, Unit investment trusts, Closed-end funds, Rydex funds, Credit income fund and others.